Detalhe da pesquisa
1.
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 384(16): 1529-1541, 2021 04 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33882206
2.
The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results.
Future Oncol
; 20(1): 5-16, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37916267
3.
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
Oncologist
; 28(10): e867-e876, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37589218
4.
Impact of early palliative care on additional line of chemotherapy in metastatic breast cancer patients: results from the randomized study OSS.
Support Care Cancer
; 31(1): 82, 2022 Dec 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36574052
5.
Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic.
Br J Cancer
; 125(11): 1486-1493, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34588616
6.
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up.
Oncologist
; 26(5): e749-e755, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33486783
7.
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
N Engl J Med
; 379(22): 2108-2121, 2018 11 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-30345906
8.
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(1): 44-59, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31786121
9.
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(10): 1269-1282, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32861273
10.
Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis.
Breast Cancer Res Treat
; 180(3): 597-609, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32100144
11.
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.
Breast Cancer Res Treat
; 184(1): 161-172, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32789591
12.
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial.
Breast Cancer Res
; 21(1): 121, 2019 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31727113
13.
A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
Int J Cancer
; 145(7): 1902-1912, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30859564
14.
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.
Br J Cancer
; 121(12): 991-1000, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31719684
15.
Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.
Oncologist
; 24(12): 1514-1525, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31217344
16.
Palbociclib and Letrozole in Advanced Breast Cancer.
N Engl J Med
; 375(20): 1925-1936, 2016 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-27959613
17.
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.
Breast Cancer Res Treat
; 177(2): 383-393, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31172407
18.
ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.
Future Oncol
; 15(19): 2211-2225, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31074641
19.
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
Invest New Drugs
; 36(5): 848-859, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29349598
20.
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 18(6): 732-742, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28526536